Physician profile
Amar Sawar
NPI 1245280445
$4,388.11
in general payments reported to CMS, 2019-2025
49 companies · $436 in 2025
The $436 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $303 · 2021: $906 · 2022: $926 · 2023: $598 · 2024: $987 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,822.47 |
| Education | $198.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $538.26 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $477.76 | 2020-2021 | |
| Eisai INC. | $444.63 | 2021-2025 | |
| Abbvie INC. | $327.97 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $290.83 | 2022-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $226.09 | 2020-2025 | Tavneos, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $212.08 | 2022 | |
| Lilly USA, LLC | $194.73 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $187.77 | 2022-2025 | Rytary, Crexont, Ongentys |
| Novartis Pharmaceuticals Corporation | $139.47 | 2020-2024 | |
| Biogen, INC. | $107.95 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $107.94 | 2021-2024 | Orencia |
| Lundbeck LLC | $95.13 | 2024-2025 | Vyepti |
| Harmony Biosciences LLC | $88.29 | 2023-2024 | Wakix |
| Astrazeneca Pharmaceuticals LP | $70.02 | 2022-2024 | Saphnelo |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Sawar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.